BOPA will take a stand on the healthcare issues that affect oncology pharmacy and cancer patients. Our position statements are there to promote the best interests of our members. They are independently produced by the committee in consultation with our members. We will also from time to time survey members and will publish the results of our surveys here.
Survey of the oncology pharmacy workforce (2017)A Survey of the oncology pharmacy workforce and assessment of capability to undertake advanced roles in the cancer setting. In April 2017 th BOPA committee undertook a workforce survey of the BOPA membership in February 2017. This poster presents the results of the survey
BOPA Position Statement on working with Pharmaceutical IndustryThis position statement outlines BOPA's relationship with the pharmaceutical industry and BOPA’s views on the provision of medical education for its members via Industry sponsorship.
The position statement aims to provide open and transparent information on: how BOPA works with the pharmaceutical industry BOPA’s financial relationship with its Secretariat how BOPA manages its finances (as a registered charity, see below) how BOPA supports its members to avoid any conflict of interest
Biosimilar MABs Implementation Guidance February 2017This document describes the evidence, recommendations and practical considerations for adoption of biosimilar MABs. It also contains BOPA's position statement on biosimilar monoclonal antibodies used in oncology.
Biosimilar Monoclonal Antibody Position Statement (Feb 2017)The British Oncology Pharmacy Association’s (BOPA) position is that biosimilar monoclonal antibodies (MABs) are therapeutically equivalent to the originator molecules and can and should be used for all commissioned indications, provided pharmacovigilance safeguards are in place, e.g. branded prescribing. BOPA’s full position statement, which should be read in conjunction with BOPA's implimentation guidelines is below.